FIELD: biotechnology; genetic engineering.
SUBSTANCE: invention relates to biotechnology and genetic engineering; it consists in using a sequence in a heavy chain selected from
or a sequence in a light chain selected from
to obtain genetically constructed antibody with cysteine substitutions containing free amino acid cysteine with thiol reactivity value of approximately 0.8 or higher, where cysteine in the sequence is free amino acid cysteine, and where antibody retains a capability of binding antigen, or to obtain immunoconjugate containing genetically constructed antibody with cysteine substitutions.
EFFECT: invention allows for using antibodies and compounds of antibody-drug conjugates for diagnosing or treating in vitro, in situ and in vivo mammalian cells or pathological states related to them.
21 cl, 11 dwg, 8 tbl, 12 ex
| Title | Year | Author | Number |
|---|---|---|---|
| HUMAN ANTIBODIES BINDING TO ROR2 | 2018 |
|
RU2784586C2 |
| CONJUGATES OF ANTIBODY TO CCR7 AND DRUG | 2018 |
|
RU2777662C2 |
| ANTI-CD79B ANTIBODIES, IMMUNOCONJUGATES AND METHODS FOR THEIR USE | 2019 |
|
RU2791984C2 |
| CONJUGATES OF ANTIBODIES TO STAPHYLOCOCCUS AUREUS WITH RIFAMYCIN AND USE THEREOF | 2015 |
|
RU2731055C2 |
| STABLE COMPOSITIONS OF ANTI-TIGIT ANTIBODIES, INDIVIDUALLY AND IN COMBINATION WITH ANTIBODIES AGAINST PROGRAMMED DEATH RECEPTOR 1 (PD-1), AND METHODS OF THEIR USE | 2018 |
|
RU2820576C2 |
| ANTIBODIES WHICH BIND TO SORTILIN AND INHIBIT THE BINDING OF PROGRANULIN | 2016 |
|
RU2735639C2 |
| Therapeutic antibodies to CD47 | 2016 |
|
RU2748401C2 |
| T-CELL RECEPTORS SPECIFIC RELATIVELY TO COMPLEX OF TUMOR ANTIGEN NY-ESO-1/HLA-A*02 | 2016 |
|
RU2775394C2 |
| SUBUNIT VACCINE FOR TREATING OR PREVENTING RESPIRATORY TRACT INFECTION | 2020 |
|
RU2811991C2 |
| ANTIBODIES TO ENTPD2, TYPES OF COMBINATION THERAPY AND METHODS FOR USING ANTIBODIES AND TYPES OF COMBINATION THERAPY | 2019 |
|
RU2790991C2 |
